112 De Monte L, Reni M, Tassi E *et al.* Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. *J. Exp. Med.* 208(3), 469–478 (2011).

113 Aspord C, Pedroza-Gonzalez A, Gallegos M *et al.* Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. *J. Exp. Med.* 204(5), 1037–1047 (2007).

114 Pedroza-Gonzalez A, Xu K, Wu TC *et al.* Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. *J. Exp. Med.* 208(3), 479–490 (2011).

115 Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. *Annu. Rev. Immunol.* 27, 485–517 (2009).

116 Littman DR, Rudensky AY. Th17 and regulatory T cells in mediating and restraining inflammation. *Cell* 140(6), 845–858 (2010).

117 Murugaiyan G, Saha B. Protumor vs antitumor functions of IL-17. *J. Immunol.* 183(7), 4169–4175 (2009).

118 Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. *Nat. Rev. Immunol.* 10(4), 248–256 (2010).

119 Kryczek I, Banerjee M, Cheng P *et al.* Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. *Blood* 114(6), 1141–1149 (2009).

120 Zhang JP, Yan J, Xu J *et al.* Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. *J. Hepatol.* 50(5), 980–989 (2009).

121 Sfanos KS, Bruno TC, Maris CH *et al.* Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. *Clin. Cancer Res.* 14(11), 3254–3261 (2008).

122 Koyama K, Kagamu H, Miura S *et al.* Reciprocal CD4+ T-cell balance of effector CD62L^low CD4+ and CD62L^high CD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage. *Clin. Cancer Res.* 14(21), 6770–6779 (2008).

123 Liu J, Duan Y, Cheng X *et al.* IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. *Biochem. Biophys. Res. Commun.* 407(2), 348–354 (2011).

124 Maruyama T, Kono K, Mizukami Y *et al.* Distribution of Th17 cells and FoxP3^(+) regulatory T cells in tumor-infiltrating lymphocytes, tumor-draining lymph nodes and peripheral blood lymphocytes in patients with gastric cancer. *Cancer Sci.* 101(9), 1947–1954 (2010).

125 Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF, Peng G. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. *J. Immunol.* 184(3), 1630–1641 (2010).

126 Hayday AC. γδ T cells and the lymphoid stress-surveillance response. *Immunity* 31(2), 184–196 (2009).

127 Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human γδ T cells. *Science* 309(5732), 264–268 (2005).

128 Girardi M, Oppenheim DE, Steele CR *et al.* Regulation of cutaneous malignancy by γδ T cells. *Science* 294(5542), 605–609 (2001).

129 Ma Y, Aymeric L, Locher C *et al.* Contribution of IL-17-producing {γ}{δ} T cells to the efficacy of anticancer chemotherapy. *J. Exp. Med.* 208(3), 491–503 (2011).

130 Ke Y, Kapp LM, Kapp JA. Inhibition of tumor rejection by γδ T cells and IL-10. *Cell Immunol.* 221(2), 107–114 (2003).

131 Bonneville M, Scotet E. Human Vγ9Vδ2 T cells: promising new leads for immunotherapy of infections and tumors. *Curr. Opin Immunol.* 18(5), 539–546 (2006).

132 Martinet L, Poupot R, Fournié JJ. Pitfalls on the roadmap to γδ T cell-based cancer immunotherapies. *Immunol. Lett.* 124(1), 1–8 (2009).

133 Raspollini MR, Castiglione F, Rossi Degl'innocenti D *et al.* Tumour-infiltrating γ/δ T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. *Ann. Oncol.* 16(4), 590–596 (2005).

134 Inman BA, Frigola X, Harris KJ *et al.* Questionable relevance of γ δ T lymphocytes in renal cell carcinoma. *J. Immunol.* 180(5), 3578–3584 (2008).

135 Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH, Wang RF. Tumor-infiltrating γδ T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. *Immunity* 27(2), 334–348 (2007).

136 Nelson BH. CD20+ B cells: the other tumor-infiltrating lymphocytes. *J. Immunol.* 185(9), 4977–4982 (2010).

137 Coronella-Wood JA, Hersh EM. Naturally occurring B-cell responses to breast cancer. *Cancer Immunol. Immunother.* 52(12), 715–738 (2003).

138 DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. *Breast Cancer Res.* 9(4), 212 (2007).

139 Schmidt M, Böhm D, von Törne C *et al.* The humoral immune system has a key prognostic impact in node-negative breast cancer. *Cancer Res.* 68(13), 5405–5413 (2008).

140 Milne K, Köbel M, Kalloger SE *et al.* Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. *PLoS ONE* 4(7), e6412 (2009).

141 Nedergaard BS, Ladekarl M, Nyengaard JR, Nielsen K. A comparative study of the cellular immune response in patients with stage IB cervical squamous cell carcinoma. Low numbers of several immune cell subtypes are strongly associated with relapse of disease within 5 years. *Gynecol. Oncol.* 108(1), 106–111 (2008).

142 Sorbye SW, Kilvaer T, Valkov A *et al.* Prognostic impact of lymphocytes in soft tissue sarcomas. *PLoS ONE* 6(1), e14611 (2011).

143 Dieu-Nosjean MC, Antoine M, Danel C *et al.* Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. *J. Clin. Oncol.* 26(27), 4410–4417 (2008).

144 Distel LV, Fickenscher R, Dietel K *et al.* Tumour infiltrating lymphocytes in squamous cell carcinoma of the oro- and hypopharynx: prognostic impact may depend on type of treatment and stage of disease. *Oral Oncol.* 45(10), E167–E174 (2009).

145 Simsa P, Teillaud JL, Stott DI, Tóth J, Kotlan B. Tumor-infiltrating B cell immunoglobulin variable region gene usage in invasive ductal breast carcinoma. *Pathol. Oncol. Res.* 11(2), 92–97 (2005).

146 Jinushi M, Hodi FS, Dranoff G. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. *Immunol. Rev.* 222, 287–298 (2008).

147 Ljunggren HG, Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer. *Nat. Rev. Immunol.* 7(5), 329–339 (2007).

148 Albertsson PA, Basse PH, Hokland M *et al.* NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. *Trends Immunol.* 24(11), 603–609 (2003).

149 Coca S, Perez-Piqueras J, Martinez D *et al.* The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. *Cancer* 79(12), 2320–2328 (1997).

150 Ishigami S, Natsugoe S, Tokuda K *et al.* Prognostic value of intratumoral natural killer cells in gastric carcinoma. *Cancer* 88(3), 577–583 (2000).

151 Villegas FR, Coca S, Villarrubia VG *et al.* Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. *Lung Cancer* 35(1), 23–28 (2002).

152 Maréchal R, De Schutter J, Nagy N *et al.* Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients. *BMC Cancer* 10, 340 (2010).

153 Schleypen JS, Baur N, Kammerer R *et al.* Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. *Clin. Cancer Res.* 12(3 Pt 1), 718–725 (2006).

154 Carrega P, Morandi B, Costa R *et al.* Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56^{bright} CD16$^{(-)}$ cells and display an impaired capability to kill tumor cells. *Cancer* 112(4), 863–875 (2008).

155 Halama N, Braun M, Kahlert C *et al.* Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. *Clin. Cancer Res.* 17(4), 678–689 (2011).

156 Bendelac A, Savage PB, Teyton L. The biology of NKT cells. *Annu. Rev. Immunol.* 25, 297–336 (2007).

157 Dhodapkar MV. Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges. *Front. Biosci.* 14, 796–807 (2009).

158 Song L, Asgharzadeh S, Salo J *et al.* Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. *J. Clin. Invest.* 119(6), 1524–1536 (2009).

159 Motohashi S, Nakayama T. Clinical applications of natural killer T cell-based immunotherapy for cancer. *Cancer Sci.* 99(4), 638–645 (2008).

160 Tahir SM, Cheng O, Shaulov A *et al.* Loss of IFN-γ production by invariant NK T cells in advanced cancer. *J. Immunol.* 167(7), 4046–4050 (2001).

161 Motohashi S, Kobayashi S, Ito T *et al.* Preserved IFN-α production of circulating Vα24 NKT cells in primary lung cancer patients. *Int. J. Cancer* 102(2), 159–165 (2002).

162 Crough T, Purdie DM, Okai M, Maksoud A, Nieda M, Nicol AJ. Modulation of human Vα24$^{(+)}$Vβ11$^{(+)}$ NKT cells by age, malignancy and conventional anticancer therapies. *Br. J. Cancer* 91(11), 1880–1886 (2004).

163 Tachibana T, Onodera H, Tsuruyama T *et al.* Increased intratumor Vα24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. *Clin. Cancer Res.* 11(20), 7322–7327 (2005).

164 Dhodapkar MV, Geller MD, Chang DH *et al.* A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. *J. Exp. Med.* 197(12), 1667–1676 (2003).

165 Bricard G, Cesson V, Devevre E *et al.* Enrichment of human CD4^{+} V(α)24/Vβ11 invariant NKT cells in intrahepatic malignant tumors. *J. Immunol.* 182(8), 5140–5151 (2009).

166 Gulubova M, Manolova I, Kyurkchiev D, Julianov A, Altunkova I. Decrease in intrahepatic CD56^{+} lymphocytes in gastric and colorectal cancer patients with liver metastases. *APMIS* 117(12), 870–879 (2009).

167 Metelitsa LS, Wu HW, Wang H *et al.* Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. *J. Exp. Med.* 199(9), 1213–1221 (2004).

168 Byers RJ, Hitchman ER. Quantum dots brighten biological imaging. *Prog Histochem Cytochem*, 45(4), 201–237 (2011).

169 Kalyuzhny AE. The dark side of the immunohistochemical moon: industry. *J. Histochem. Cytochem.* 57(12), 1099–1101 (2009).

170 Couchman JR. Commercial antibodies: the good, bad, and really ugly. *J. Histochem. Cytochem.* 57(1), 7–8 (2009).

171 Woo YL, Sterling J, Crawford R, van der Burg SH, Coleman N, Stanley M. FOXP3 immunohistochemistry on formalin-fixed paraffin-embedded tissue: poor correlation between different antibodies. *J. Clin. Pathol.* 61(8), 969–971 (2008).

172 Casado JG, Soto R, DelaRosa O *et al.* CD8 T cells expressing NK associated receptors are increased in melanoma patients and display an effector phenotype. *Cancer Immunol. Immunother.* 54(12), 1162–1171 (2005).

173 Haanen JB, van Oijen MG, Tirion F *et al.* *In situ* detection of virus- and tumor-specific T-cell immunity. *Nat. Med.* 6(9), 1056–1060 (2000).

174 Skinner PJ, Daniels MA, Schmidt CS, Jameson SC, Haase AT. Cutting edge: *in situ* tetramer staining of antigen-specific T cells in tissues. *J. Immunol.* 165(2), 613–617 (2000).

175 Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. *Nat. Rev. Immunol.* 8(4), 247–258 (2008).

176 Yuan J, Gnjatic S, Li H *et al.* CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. *Proc. Natl Acad. Sci. USA* 105(51), 20410–20415 (2008).

177 Attig S, Hennenlotter J, Pawelec G *et al.* Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. *Cancer Res.* 69(21), 8412–8419 (2009).

178 Tran E, Nielsen JS, Wick DA *et al.* Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines. *PLoS ONE* 5(12), e15625 (2010).

Phase II Study of Personalized Peptide Vaccination for Castration-Resistant Prostate Cancer Patients Who Failed in Docetaxel-Based Chemotherapy

Masanori Noguchi,[1,2]* Fukuko Moriya,[2] Shigetaka Suekane,[2] Kei Matsuoka,[2] Gaku Arai,[3] Satoko Matsueda,[4] Tetsuro Sasada,[4] Akira Yamada,[5] and Kyogo Itoh[4]

[1]Division of Clinical Research of the Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan
[2]Departments of Urology, Kurume University School of Medicine, Kurume, Japan
[3]Department of Urology, Dokkyo Medical University Koshigaya Hospital, Koshigaya, Japan
[4]Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
[5]Division of Cancer Vaccine of the Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan

BACKGROUND. Docetaxel-based chemotherapy (DBC) showed limited clinical efficacy for castration-resistant prostate cancer (CRPC) patients. To explore cancer vaccine as a new treatment modality, we conducted a phase II study of personalized peptide vaccine (PPV) for DBC-resistant CRPC patients.

METHODS. Twenty DBC-resistant CRPC patients and 22 patients with no prior DBC, as a control, were treated with PPV using peptides chosen from 31 peptides in patients, respectively. Cytokines, inflammatory markers, and immune responses were measured as candidate biomarkers. DBC-resistant CRPC patients without PPV was set as a historical control for evaluation of clinical benefit of PPV.

RESULTS. Median overall survival (OS) time from the first vaccination was 14.8 months or not reached in DBC-resistant CRPC patients and patients with no prior DBC (log-rank; $P = 0.07$), respectively. Median OS time from the first day of progression disease was 17.8 and 10.5 months in DBC-resistant CRPC patients receiving PPV and those with no PPV ($P = 0.1656$), respectively. Elevated IL-6 levels before vaccination was an unfavorable factor for OS of DBC-resistant CRPC patients ($P = 0.0161$, hazard ratio (HR): 0.024, 95% CI:0.001–0.499) as well as all 42 patients with PPV($P = 0.0011$, HR: 0.212, 95% CI:0.068–0.661) by multivariable analysis.

CONCLUSIONS. Further clinical study of PPV is recommended for DBC-resistant CRPC patients, because of the safety and possible prolongation of MST. Control of elevated IL-6 by combined therapy may provide much better clinical outcome. *Prostate* © 2011 Wiley-Liss, Inc.

KEY WORDS: personalized peptide vaccine; prostate cancer; docetaxel; overall survival

INTRODUCTION

Castration-resistant prostate cancer (CRPC) is the second-most common cause of cancer-related death in men in the developed world [1,2]. For patients with metastatic prostate cancer, androgen deprivation therapy improves symptoms, but patients invariably develop progressive disease (PD). In the 1990s, the US

Food and Drug Administration (FDA) approved mitoxantrone and corticosteroids for use in prostate cancer after a demonstrated improvement in palliative benefit over steroids alone [3,4]. In 2004, two large, randomized, phase III trials with docetaxel-based chemotherapy (DBC) showed an improvement in overall survival (OS) as well as patients' reported outcomes [5,6]. These studies changed the goal of treatment in CRPC patients from pure palliation to a survival benefit and represent a milestone in the treatment of the disease. Although DBC represents the most active chemotherapy for first-line treatment of metastatic CRPC, all patients experience disease progression and the median survival benefit with DBC is only 2–3 months. Currently, there is no standard treatment and median OS of second-line approaches after a therapy with DBC are in the range of 12 months [7]. Clearly, the prognosis is very poor, and new treatments that might favorably affect survival for CRPC patients with progression after DBC are obviously needed.

Prostate cancer arises in a relatively unique organ and may express a number of antigens against which an immune response can be generated. Several of these agents have now demonstrated a significant survival benefit in randomized controlled clinical trials for CRPC patients, and Sipuleucel-T (Provenge, Dendreon Corporation, Seattle, WA) which is a fusion protein between the target antigen [prostatic acid phosphatase (PAP)] and granulocyte monocyte colony stimulating factor (GM-CSF), was approved for CRPC patients by the FDA in 2010. However, the survival benefit of this immunotherapy for CRPC patients with progression after DBC has been under investigation.

Personalized peptide vaccine (PPV) is a multiple peptide vaccine regimen planned according to the pre-existing immunity that could prolong OS of patients with advanced cancer. Under PPV treatment, each patient was tested for their immunological reactivity to many different peptides capable of inducing cytotoxic-T-lymphocyte (CTL) responses. The peptides were derived from a number of targets, including prostate-specific antigen (PSA), PAP, prostate-specific membrane antigen (PSMA), multidrug resistance protein, and a variety of other epithelial tumor antigens. Each patient was immunized with 2–4 peptides on the basis of the reactivity panel, since immune responses to individual peptides are usually quite heterogeneous. The most unique aspect of PPV is the "personalized" selection of antigen peptides ideal for individual patients in consideration of the pre-existing host immunity before vaccination. In view of the heterogeneity and complexity of host immune responses and/or tumors, this approach seems to be

more rational, rather than vaccination with non-personalized "universal" tumor antigens. Based on the current paradigm that the adaptive immune system composes of limited size and composition, in which individual cells constantly compete with each other, "inconvenient" immune responses induced by non-personalized antigens that are either non-specific to tumor cells or ineffective for tumor cell killing may cause suppression of pre-existing beneficial immunity, which may lead to poor prognosis in vaccinated patients. Indeed, in our previous clinical trials with non-personalized vaccine regimens, some advanced cancer patients showed a shorter survival than expected, possibly because of the inhibition of pre-existing host immunity [8,9]. In contrast, our recent randomized trials of PPV in consideration of the pre-existing host immunity in individual patients have clearly demonstrated clinical benefit to the CRPC patients [10]. To preliminarily investigate the efficacy and safety of the PPV in CRPC patients while evaluating progression status with or without prior DBC, we prospectively undertook a non-randomized, open-label phase II trial.

PATIENTS AND METHODS

Eligibility

Patients were eligible for inclusion in the study, if they had a histological diagnosis of prostate adenocarcinoma and PD by clinical, radiological, or PSA-based criteria, despite adequate medical or surgical castration therapy with or without prior DBC, and showed positive humoral responses to at least two of the 31 different, candidate peptides, determined by both human leukocyte antigen (HLA)-class IA types and the titers of IgG against each peptide. Any number of previous hormonal therapies was allowed. Patients were required to wait at least 4 weeks for entry into the study after the completion of prior chemotherapy, radiation therapy, or a change in hormonal therapy. Anti-androgen therapy was discontinued for at least 4 weeks before enrollment for patients receiving flutamide, and 6 weeks for those receiving bicalutamide. Additional inclusion criteria included age ≥20 years; Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1; positive status for HLA-A2, -A24, -A3 super type (-A3, -A11, -A31, and -A33) or -A26; life expectancy of at least 12 weeks; negative status for hepatitis virus B and C; adequate hematologic, hepatic, and renal function. Exclusion criteria included pulmonary, cardiac, or other systemic diseases; an acute infection; a history of severe allergic reactions; other inappropriate conditions for enrollment judged by clinicians.

The protocol was approved by the Kurume University Ethical Committee, and was registered in UMIN-CTR (UMIN000003028). After full explanation of the protocol, written informed consent was obtained from all patients before enrollment.

Study Design and Treatment

This study was a non-randomized, open-label, phase II study and the primary and secondary endpoints were OS, and to evaluate immunological activity and safety in CRPC patients under treatment with PPV, respectively. OS was calculated from date of start of vaccination to any causes of death.

Thirty one peptide candidates were prepared under conditions of Good Manufacturing Practice using a Multiple Peptide System (San Diego, CA) and American Peptide Company (Vista, CA). The candidate peptides consisted of the following 31: SART3 $_{302-310}$, SART3 $_{309-317}$, Lck $_{246-254}$, WHSC2 $_{141-149}$, UBE2V $_{43-51}$, UBE2V $_{85-93}$, and HNRPL $_{140-148}$ for patients with HLA-A2; SART2 $_{93-101}$, SART2 $_{161-169}$, Lck $_{208-216}$, Lck$_{486-494}$, Lck $_{488-497}$, MRP3 $_{503-511}$, MRP3 $_{1293-1302}$, PAP $_{213-221}$, PSA $_{248-257}$, PSMA $_{624-624}$, EZH2 $_{735-743}$, EGF-R $_{800-809}$, and PTH-rP $_{102-111}$ for patients with HLA-A24; SART3 $_{511-519}$, SART3 $_{734-742}$, Lck $_{90-99}$, Lck $_{449-458}$, and PAP $_{248-257}$ for patients with HLA-A3 super type; SART3 $_{109-118}$ for patients with HLA-A24, -A3 super type or -A26; WHSC2 $_{103-111}$ for HLA-A2, -A3 super type or -A26; ppMAPkkk $_{432-440}$ for patients with HLA-A2 or -A26; HNRPL $_{501-510}$ for patients with HLA-A2 or -A26; CypB $_{129-138}$ for patients with HLA-A2 or -A3 super type; Lck $_{422-430}$ for patients with HLA-A2 or -A3 super type. Original proteins of the employed peptides, except for Lck and MRP3, are ubiquitously expressed on various tissues and organs with preferential expression in malignant cells [11,12]. The lck is expressed on metastatic cancer cells [13], although originally identified as a T cell-specific tyrosine–kinase. The MRP3 is an ATP-binding cassette transporter related to multi-drug resistance of cancer cells [14].

The safety and immunological effects of these 31 peptides had been confirmed in conducted clinical trials [10,15–22].

The selection of the right peptides for vaccination to individual patients were based on the results of HLA typing and peptide-specific IgG titers to each of the 31 different vaccine candidates as reported previously [10,15–22]. Selected peptides were mixed with incomplete Freund's adjuvant (Montanide ISA-51VG; Seppic, Paris, France), and a maximum of four peptides of 1.5 ml emulsion each at a dose level of 3 mg/peptide were injected subcutaneously into the thigh or armpit area once a week for six times. The

Montanide ISA51VG was used as an adjuvant in the current study, since it is the most popular in clinical use to induce cellular immunity and has been employed in the majority of peptide vaccine trials in the world [23].

After the first cycle of six vaccinations of up to four antigen peptides, the antigen peptides were re-selected according to the titers of peptide-specific IgG at every cycle of six vaccinations and administered at 2, 3, or 4 week intervals until unacceptable toxicity or withdrawal of consent.

Assessment of Clinical Activity

A complete survey of medical history, physical examination, routine laboratory studies, and serum PSA test were performed prior to treatment, and tests were repeated at every six vaccinations. To investigate biomarkers for OS, C-reactive protein (CRP), serum amyroid A (SAA), and interleukin (IL)-6 in plasma at base line were examined by enzyme-linked immunosorbent assay (ELISA) using the kits from R&D systems (Minneapolis, MN), Invitrogen, and eBioscience (San Diego, CA), respectively. Multiplexed bead-based Luminex assays were used to measure IL-6. Frozen plasma samples were thawed, diluted, and assayed in duplicate in accordance with the manufacturer's instructions. All patients underwent relevant radiologic studies and bone scans every 6 months. Outcomes were assessed by post-therapy changes in serum PSA and by computed tomography (CT) or magnetic resonance imaging (MRI) of measurable disease symptoms if present at the baseline. Post-therapy decreases in PSA level of $\geq 50\%$ were defined as partial responses (PR) and confirmed by two separate measurements ≥ 4 weeks apart. Post-therapy decreases of less than 50% or increases of less than 25% from the baseline were interpreted as stable disease (SD) [24]. For measurable disease symptoms, Response Evaluation Criteria in Solid Tumors was used [25]. PD was defined as radiological progression, or if defined using PSA level alone, three consecutive increases in PSA level and 125% of the baseline PSA value. Toxicity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI-CTC Ver4).

Measurement of Humoral and T-Cell Responses Specific to the Vaccinated Peptides

The humoral responses specific to the vaccinated peptides were determined by peptide-specific IgG levels using a Luminex system (Luminex, Austin, TX), as reported previously [26]. If the titers of peptide-specific IgG in the post-vaccination plasma were

more than twofold higher than those in the pre-vaccination plasma, the changes were considered to be significant. If a significant increase was observed in at least one vaccinated peptide, the specific humoral response was considered to be augmented.

Although T-cell subsets using flowcytometry was not analyzed in this study, T-cell responses specific to the vaccinated peptides were evaluated by INF-γ ELISPOT using peripheral blood mononuclear cells (PBMCs), which were separated from peripheral blood (30 ml) by density gradient centrifugation with Ficoll-Paque Plus (GE Healthcare; Uppsala, Sweden) and stored frozen until analysis. After thawing, PBMCs (2.5×10^4 cells/well) were incubated in 384-well microculture plates (IWAKI, Tokyo, Japan) with 25 μl of medium (OpTmizer^{TM} T Cell Expansion SFM; Invitrogen, Carlsbad, CA) containing 10% FBC (MP Biologicals, Solon, OH), IL-2 (20 IU/ml; Serotec, Oxford, UK), and each peptide (10 μM). Half of the medium was removed and replaced with new medium containing a corresponding peptide (20 μM) after culturing for 3 days. After incubating for the following 6 days, the cells were harvested and tested for their ability to produce interferon (IFN)-γ in response to either the corresponding peptides or a negative control peptide human immunodeficiency virus (sequences: SLYNTYATL for HLA-A2; RYLRQQLLGI for HLA-A24; RLRDLLLIVTR for HLA-A3 supertype; EVIPMFSAL for HLA-A26). Antigen-specific IFN-γ secretion after an 18 hr incubation was determined by ELISPOT, according to the manufacturer's instructions (MBL, Nagoya, Japan). All assays were carried out in triplicate and analyzed with an ELISPOT reader (CTL-ImmunoSpot S5 Series; Cellular Technology Ltd, Shaker Heights, OH). Antigen-specific T-cell responses were evaluated by the difference between the spot numbers in response to the corresponding peptide and those to the control peptide; differences of threefold were considered significant. If the spot numbers in response to the corresponding peptide in the post-vaccination PBMCs were more than threefold higher than those in the pre-vaccination PBMCs, the changes were considered to be significant. If a significant increase was observed in at least one vaccinated peptide, the specific T-cell response was considered to be augmented.

Statistical Analysis

Demographics were compared between groups using χ^2 test or Fisher's exact test for categorical variables and the Student's t-test for continuous variables. Probabilities of progression free survival (PFS) and OS in patients with PPV were estimated from the first date of peptide vaccination to PD or death using

Kaplan–Meier methods. In comparison of OS between the patients with PPV with prior DBC and PD patients as the matched control cohort, OS were estimated from the date of PD after DBC to death in order to assess uniformly. All analyses are by intent to treat. Surviving patients were censored at October 7, 2010, with follow-up of 97% complete. Patients lost to follow-up are censored at the date last known to be alive. Cox proportional hazard regression analysis was used to develop the univariate and multivariate models describing the association of the independent variables with OS. Independent variables analyzed included age, EOCG performance status, lymphocyte counts, PSA, CRP, SAA, IL-6, prior DBC status, IgG responses, and T-cell responses. All baseline parameters in the models were analyzed as dichotomous variables using cut-off values. Data were analyzed using GraphicPad Prism software (GraphPad Software, San Diego, CA) and the StatView$^{®}$ program (SAS Institute Inc., Cary, NC). A two-sided significance level of 5% was considered statistically significant.

RESULTS

Patients' Characteristics

Between November 2008 and April 2010, 42 patients with CRPC (20 with prior DBC and 22 without prior DBC) were enrolled into this study. All patients with DBC received 60–75 mg/m^2 docetaxel and repeated every 3–4 weeks in combination with oral prednisone (10 mg/day) or dexamethasone (2 mg/day). Median cycle of docetaxel was 6.5 and failed in treatment. Baseline patient characteristics were well balanced between two study cohorts. No statistically significant differences existed between the groups excluding prior DBC. There was no correlation between Gleason score and pre-vaccine PSA doubling times. Before the enrollment all patients received androgen deprivation therapy using luteinizing hormone-releasing hormone (LH-RH) analogue (or had previously undergone castration) or anti-androgen as an initial or secondary hormonal therapy. All patients were eligible and assessable. The control group at the Dokkyo Medical University Koshigaya Hospital represented 17 patients initiating DBC between September 2007 and August 2010. Table I shows patients' characteristics of the study and control group at the Dokkyo Medical University Koshigaya Hospital. The study cohort with prior DBC and control group were well matched regarding median age, ECOG performance status, and median cycle of DBC (6.5 cycles vs. 7 cycles). The study cohort had a higher level of median PSA levels and higher metastatic sites than the control group.

TABLE I. Patient Demographics and Clinical Characteristics

	PPV				Matched control PD after DBC (n = 17)	
	Without prior DBC (n = 22)		With prior DBC (n = 20)			
Characteristics	No. of Patients	%	No. of Patients	%	No. of Patients	%
Age, years						
Median	70.5		70		71	
Range	53–87		61–81		54–80	
ECOG performance status						
0	22	100	17	85	15	88
1	0	0	3	15	2	12
HLA typing						
A24	16	73	13	65	—	—
A2	4	18	4	20	—	—
A3 super type	2	9	3	15	—	—
PSA, ng/ml						
Median	23.4		87.8		14.7	
Range	0–1,920		4.2–1,508		0.016–317	
PSA doubling time, months						
Median	2.7		3.4		—	—
Range	0.5–36		1.4–60		—	—
Lymphocyte, 1,400 μl^{-1}						
Low	8	36	10	50	—	—
High	14	64	10	50	—	—
CRP, 3,000 ng/ml						
Low	11	50	8	40	—	—
High	11	50	12	60	—	—
SAA, 20,000 ng/ml						
Low	13	59	3	15	—	—
High	9	41	17	85	—	—
IL6, 2 pg/ml						
Low	19	86	15	75	—	—
High	3	14	5	25	—	—
Gleason score						
6	1	4	2	10	0	0
7	6	28	6	30	4	23
8	3	14	1	5	3	18
9	10	46	8	40	8	47
10	1	4	2	10	2	12
Unknown	1	4	1	5	0	0
Site of metastasis						
No	3	14	0	0	4	23
Bone only	7	32	9	45	7	42
Bone and nodal/organ	10	46	9	45	2	12
Nodal/organ	2	8	2	10	4	23
Cycle of DBC						
Median	—		6.5		7	
Range	—		1–27		2–19	

PPV, personalized peptide vaccination; DBC, docetaxel-based chemotherapy; PD, progression disease; ECOG, Eastern Cooperative Oncology Group; HLA, human leicocyte antigen; PSA, prostate-specific antigen; CRP, C reactive protein; SAA, serum amyroid A; IL6, interleukin 6.

Peptides Selection and Immune Responses

Before the peptide vaccination, anti-peptide IgG levels were examined in all 42 patients, and two to four peptides were selected for each patient. The most frequently selected peptides were SART2 $_{161-169}$ (14/42), SART3 $_{109-118}$ (13/42), MRP3 $_{503-511}$ (12/42), Lck $_{486-494}$ (9/42), PAP $_{213-221}$ (8/42), HNRPL $_{501-510}$ (8/42), and MRP3 $_{1293-1302}$ (7/42). Lck $_{246-254}$, WHSC2 $_{141-149}$, and SART3 $_{309-317}$ were not selected in this trial.

Both humoral and T-cell responses specific to the vaccinated peptides were analyzed in blood samples before and after the sixth vaccination. Plasma samples were obtained from all patients before and at the time of the sixth vaccination. The post-vaccination samples were not available in one patient with prior DBC, who failed to complete the first cycle of six vaccinations because of disease progression. Table II shows the levels of IgG and T-cell responses in each patient prior to the vaccinations and at the sixth vaccination.

For the monitoring of humoral immune responses, peptide-specific IgG titers were measured by bead-based multiplex assay. The IgG responses specific to at least one of the vaccinated peptides were revealed in 9 of 19 (47%) patients with prior DBC and in 9 of 22 (41%) patients without prior DBC at the 6th vaccination, respectively.

T-cell responses to the vaccinated peptides were measured by IFN-γ ELISPOT assay with PBMCs. PBMCs were available for this assay in 42 and 41 patients before and at the time of the 6th vaccination, respectively. In the pre-vaccination samples, antigen-specific T-cell responses were detectable in 2 of 19 (11%) patients with prior DBC and 5 of 22 (23%) patients without prior DBC, respectively. At the time of the sixth vaccination, T-cell responses to the vaccinated peptides were boosted in 6 of 19 (32%) patients with prior DBC and 8 of 22 (36%) patients without prior DBC. Collectively, antigen-specific T-cell responses were rarely detected in PMBCs before vaccination. In addition, the increase in either peptide-specific IgG titers or T-cell responses at the sixth vaccination was observed in a subset of patients. Notably, the increase in immune responses to each vaccine antigen was not uniformly robust, probably due to the heterogeneity of host immune systems.

Treatment and Efficacy

The median number of vaccinations was 13.5 (range; 5–26) in patients with prior DBC and 14 (range; 6–30) in patients without prior DBC, respectively. One patient with prior DBC did not complete the six scheduled vaccinations because of disease progression. PSA decrease by ≥50% was observed in 15%

of the patients with prior DBC and in 9% of the patients without prior DBC. No objective responses were observed in this study. During a median follow-up of 2.7 months, 17 PD occurred in patients with prior DBC; 16 patients had a PSA progression and 1 patient had a new lesion on bone scan, and 16 PD occurred in patients without prior DBC; 14 patients had a PSA progression and 2 patients had a new lesion on bone scan. The median PFS was 2.5 months (95% CI, 1.4–3.6 months) for patients treated by PPV with prior DBC and 2.6 months (95% CI, 0.8–4.4 months) for those treated by PPV without prior DBC (Fig. 1 A). The difference in PFS between the two groups was not significant (log-rank test; $P = 0.48$).

All 42 patients were analyzed for OS with a median follow-up of 11.1 months. At the time of analysis, 15 deaths had occurred; 10 (50%) in PPV with prior DBC and 5 (22.7%) in PPV without prior DBC. Median OS time was 14.8 months (95% CI, 9.7–20.0 months) in patients with prior DBC and not reached in patients without prior DBC within 22.2 months (log-rank; $P = 0.07$) (Fig. 1 B). The hazard ratio (HR) was 0.38 (95% CI, 0.13–1.13; $P = 0.081$) favoring the PPV without prior DBC group.

To assess the usefulness of PPV for patients with prior DBC, we compared the median OS time from the date of PD, after DBC was treated by PPV, with those of historical data in the Dokkyo Medical University Koshigaya Hospital in which patients did not receive PPV but had PD after DBC ($n = 17$). During a median follow-up of 15.5 months, 19 deaths had occurred; 10 (50%) in PPV with prior DBC and 9 (52.9%) in the historical group. The median OS time was 17.8 months (95% CI, 14.9–20.6 months) in patients with PPV and 10.5 months (95% CI, 7.1–14.0 months) in patients with DBC alone (log-rank; $P = 0.1656$) (Fig. 1C). The OS in the patients treated by PPV with prior DBC seemed to be more favorable than control patients with PD after DBC.

We performed Cox proportional hazard analysis to identify the prognostic factors, which were significantly associated with OS, from clinical findings or laboratory data including age, EOCG performance status, lymphocyte counts, PSA, CRP, SAA, IL-6, prior DBC status, IgG responses, and T-cell responses. As preliminary analysis, a univariate Cox analysis was carried out. IL-6 in pre-vaccine samples was only significantly associated with OS ($P = 0.0012$). None of the other factors studied were significant. Subsequently, multivariate Cox regression analysis was performed to evaluate the influence of each factor on OS after adjusting for possible confounding factors (Table III). The factors showing P less than 0.1 in the univariate analysis including IL6 ($P = 0.0012$), EOCG performance status ($P = 0.0726$), SAA ($P = 0.0632$),

TABLE II. Levels of IgG and T-Cell Responses in 42 CRPC Patients

		PPV without prior DBC (n = 22)						PPV with prior DBC			
		IgG response (FIU)		T cell response (pg/ml)				IgG response (FIU)		T-cell response (pg/ml)	
Case	Selected peptide	Pre	6th	Pre	6th	Case	Selected peptide	Pre	6th	Pre	6th
1	Lck-422	1223	2059	—	—	23	SART3-109	548	173	—	—
	ppMAPkkk-432	2893	4710	—	—		MRP3-503	158	133	—	—
	WHSC-103	1351	2513	—	—		PSMA-624	244	140	—	—
	HNRPL-140	145	1689	—	—		EZH2-735	189	132	—	—
2	SART3-109	2066	2158	—	—	24	WHSC-103	226	175	—	—
	PAP-213	1354	1134	—	—		HNRPL-140	161	119	—	—
	PSA-248	7614	7331	—	—		SART3-511	86	62	—	—
	MRP3-503	1560	1522	—	—		SART3-734	71	40	—	—
3	Lck-422	283	274	—	—	25	SART3-109	1132	619	—	—
	SART3-109	501	405	—	—		ppMAPkkk-432	58	58	—	—
	SART2-161	340	408	—	—		HNRPL-501	12	0	—	949
	Lck-486	496	581	—	—		WHSC-103	119	122	—	217
4	SART3-511	363	300	—	—	26	SART2-93	61	51	—	—
	Lck-422	358	269	—	442		SART3-109	702	0	—	—
	ppMAPkkk-432	249	422	—	—		PAP-213	254	143	—	—
	WHSC-103	755	579	—	586		SART2-161	104	76	—	—
5	WHSC-103	376	389	—	—	27	SART3-109	354	202	—	—
	HNRPL-501	359	0	—	—		WHSC2-103	305	398	—	—
	UBE2V-43	855	517	—	—		ppMAPkkk-432	213	265	—	—
	SART3-309	628	647	—	404		HNRPL-501	73	83	—	618
6	MRP3-1293	38	15	—	—		WHSC-103	305	398	—	—
	SART2-161	15	0	—	—	28	HNRPL-501	240	135	—	—
	Lck-486	23	32	—	—		SART3-511	101	0	—	—
7	PAP-213	28	1144	930	1600		SART3-734	73	58	650	—
	PSA-248	97	1119	—	—		Lck-90	46	40	—	418
	MRP3-1293	23	24	567	—	29	UBE2V-43	656	1288	—	—
	Lck-488	31	28	—	—		SART3-302	58	66	—	—
8	MRP3-503	22	27	—	—	30	UBE2V-85	15	31087	—	—
	MRP3-1293	54	59	474	—		MRP3-1293	15	0	—	—
	Lck-488	37	38	446	4514	31	PSA-248	131	30	—	—
	PSMA-624	18	26	484	407		MRP3-503	171	172	—	—
9	Lck-208	164	114	—	—		MRP3-1293	129	0	—	—
	MRP3-503	34	25	—	—		PAP-213	92	13	—	—
10	UBE2V-85	33	24	—	—		SART2-161	112	432	—	—
	EGF-R-800	12	0	—	—	32	HNRPL-501	37	0	—	—
	MRP3-503	47	0	—	757		UBE2V-43	289	12121	—	—
	PTHrP-102	55	110	—	—		UBE2V-85	51	534	—	—
11	EGF-R-800	12	0	—	—		SART3-309	28	15	—	—
	EZH2-735	22	0	—	—	33	SART3-734	166	412	—	—
	PTHrP-102	11	0	—	—		Lck-449	23	0	—	—
	PAP-248	21	0	—	—	34	SART2-93	21	0	—	1667
12	SART3-109	25549	24995	302	—		MRP3-503	54	67	—	1403
	PAP-213	16460	18292	—	—	35	SART2-93	70	86	—	—
	SART2-161	10622	16597	349	428		EGFR-800	122	154	—	—
	PTHrP-102	7929	16617	—	—		SART2-161	144	139	—	—
13	PSA-248	329	373	—	—		EZH2-735	86	192	—	—
	PTHrP-102	251	0	—	—	36	ppMAPkkk-432	262	285	—	—
14	UBE2V-85	141	103	—	—		UBE2V-85	16	13	—	—
	MRP3-503	54	57	—	—	37	PAP-213	45	24	—	—
	SART2-161	72	59	—	—		SART2-161	79	65	—	—
	Lck-486	49	1187	—	—	38	CvpB-129	87	82	—	—

(Continued)

TABLE II. *(Continued)*

		PPV without prior DBC (n = 22)						PPV with prior DBC			
		IgG response (FIU)		T cell response (pg/ml)				IgG response (FIU)		T-cell response (pg/ml)	
Case	Selected peptide	Pre	6th	Pre	6th	Case	Selected peptide	Pre	6th	Pre	6th
15	MRP3-503	11	1361	—	3443		HNRPL-501	97	105	—	3556
	SART2-161	41	77	—	2114		MRP3-503	752	18483	—	1717
16	PAP-213	25	23	—	—	39	SART3-109	2138	NA	—	NA
	MRP3-503	52	41	—	—		PSA-248	16	NA	—	NA
	SART2-161	18	16	—	—		SART2-161	23	NA	—	NA
17	CypB-129	1146	1438	—	—		Lck-486	1085	NA	—	NA
	PAP-213	185	252	—	—	40	SART2-93	77	71	—	—
	SART2-161	29	30	—	—		SART3-109	2904	3360	—	—
	Lck-486	1556	5573	680	—		MRP3-1293	112	0	279	—
18	CypB-129	10	39	—	—		Lck-486	1477	1639	—	—
	HNRPL-501	74	1449	758	14378	41	SART3-109	3273	16554	—	—
	UBE2V-43	20	367	—	2085		PSA-248	29	218	—	—
19	SART3-109	3244	0	—	—		MRP3-503	61	117	—	3457
	SART3-511	234	374	—	—		SART2-161	32	36	—	—
	Lck-90	23	25	—	—	42	SART2-93	31	0	—	—
	Lck-422	66	70	—	—		MRP3-503	13	0	—	—
20	SART2-93	622	0	—	592		SART2-161	50	0	—	454
	SART3-109	15746	162519	—	—		SART3-511	2649	6478	—	—
	Lck-486	4038	4073	—	371						
	Lck-488	2604	2170	—	—						
21	Lck-422	15	0	—	—						
	ppMAPkkk-432	44	0	—	—						
	HNRPL-501	49	0	—	276						
	UBE2V-43	189	0	—	—						
22	SART2-161	15	0	—	—						
	Lck-486	877	859	—	—						
	Lck-488	22	22	—	—						

PPV, personalized peptide vaccination; CRPC, castration-resistance prostate cancer; DBC, docetaxel based chemotherapy; NA, not available.

and prior DBC status ($P = 0.0809$) were included in multivariate analysis of the Cox proportional hazards model. Finally, a lower IL-6 value in pre-vaccine samples from all 42 patients with PPV was a significantly favorable factor for OS ($P = 0.0011$) with a HR of 0.21 (95% CI: 0.068–0.068). However, the other factors had no significant association. In addition, multivariate analysis in DBC-resistant CRP patients similarly showed that a lower IL-6 value was significantly favorable factor for OS ($P = 0.0161$) with a HR of 0.024 (95% CI: 0.001–0.499).

Toxicity

There were no grade 4 toxicities and no treatment-related deaths. The overall toxicities are shown in Table IV. The most frequent adverse events were dermatological reactions at injection sites (n = 39), lymphocytopenia (n = 15), increased AST (n = 12),

hypoalbuminemia (n = 11), and bone pain (n = 9). Severe adverse events with grade 3 were as follows: Lymphocytopenia (n = 4), increased AST (n = 2), renal failure (n = 2), bone pain (n = 1). All four patients with severe lymphocytopenia had multiple bone metastasis and progressed during PPV. Lymphocytopenia might be caused by cancer-related bone marrow suppression or immunosuppression. According to the evaluation by the independent safety evaluation committee in this trial, all of these severe adverse events were concluded to be not directly associated with the vaccinations, but with cancer progression or other causes.

DISCUSSION

Although not conclusive due to the small number of patients and the short term of observation in this early phase trial, we demonstrate that PPV is feasible,

Fig. I. Kaplan–Meier curves for (A) progression-free survival and (B) overall survival comparing PPV plus prior DBC(−) with PPV plus prior DBC(+). Kaplan–Meier curves for (C) overall survival comparing PPV plus prior DBC(+) with prior DBC alone. PPV, personalized peptide vaccination; DBC, docetaxel-based chemotherapy.

safe, and sufficiently active to induce prolonged OS and immune responses even in patients with PD after DBC. PPV was well tolerated in all patients with CRPC, and most adverse events were grade 1 or 2 local redness and swelling at the injection site. The toxicity reported here was tolerable and considered acceptable in the treatment of the vast majority of metastatic CRPC patients—especially most patients

who have a reduced performance status due to the first line DBC, older age, and non-tumor-related infliction.

In this study, median OS time was 14.8 months (95% CI, 9.7–20.0 months) in patients with prior DBC and not reached in patients without prior DBC within 22.2 months (log-rank; $P = 0.07$). The HR was 0.38 (95% CI, 0.13–1.13; $P = 0.081$) favoring the PPV without prior DBC group. Consistent with these findings, our previous studies showed a long survival in CRPC patients without prior DBC by PPV. Results from a phase I and extension study with PPV in CRPC patients without prior DBC (n = 15) showed its safety and the higher frequency of boosting immune responses with a median OS of 23.8 months [15]. Fifty-eight patients with HLA-A2 or HLA-A24 with CRPC without prior DBC were treated with a combination of PPV and low-dose estramustine phosphate (EMP) in a phase I/II study [27]. As a result, the majority (76%) of patients showed a decreased serum PSA level, along with a median OS time of 17 months (95% CI, 12–25 months). In a randomized, cross over, phase II trial of PPV plus low-dose EMP comparing standard-dose EMP in patients with CRPC without prior DBC, the median OS for the PPV plus low-dose EMP group was not reached within 22.4 months and the median OS for the standard-dose EMP group was 16.1 months (95% CI, 8.0–13.4 months) ($P = 0.0328$). The HR for OS was 0.3 in favor of the PPV plus low-dose EMP group. These results suggest that PPV is well tolerated and active in CRPC patients without prior DBC [10].

On the other hand, despite the increasing prevalence of DBC resistant prostate cancer, there are limited studies and no effective treatment in this setting. Briefly, the results of cytotoxic therapy in the second line setting have demonstrated that CRPC in general is poorly controlled after resistance to DBC with a time of progression of 3 months or less with second line therapy and a median OS of approximately 12 months [7,28]. In the current study, the median OS time in CRPC patients with prior DBC was 14.8 months. This result seemed to be a long survival in CRPC patients after PD prior DBC. Since our study was not a randomized phase II study, we attempted to compare our study results to available historical data with similar baseline prognostic features. The OS after PD prior DBC in patients with PPV was improved compared to the Dokkyo Medical University Koshigaya Hospital data. The OS in the patients treated by PPV with prior DBC seemed to be more favorable than control patients with PD after DBC (17.8 vs. 10.5 months, $P = 0.1656$). PPV may have an impact on survival in CRPC patients after PD prior DBC. However, this result was from a retrospective

TABLE III. Cox Proportional Hazards Regression Analysis of Association Between Potential Factors and Death After the PPV in the 42 CRPC Patients

Factors	Cutoffs[a]	Univariate			Multivariate		
		P-value	Hazard ratio	95% CI	P-value	Hazard ratio	95% CI
IL6	Low (<2 pg/ml) vs. high	0.0012	0.162	0.054–0.487	0.0075	0.212	0.068–0.661
SAA	Low (<20,000 ng/ml) vs. high	0.0632	0.311	0.091–1.060	0.7596	0.781	0.161–3.788
EOCG performance status	0 vs. 1	0.0726	0.307	0.084–1.115	0.3851	0.526	0.124–2.242
Prior DBC status	Untreated vs. treated	0.0809	0.380	0.128–1.126	0.4026	0.573	0.156–2.110
PSA	Low (<40 ng/ml) vs. high	0.2751	0.548	0.174–1.613	—	—	—
Pts. Age	Low (<70 years) vs. high	0.2853	0.569	0.202–1.603	—	—	—
Number of lymphocytes	High (>1,400 μl^{-1}) vs. low	0.3383	0.609	0.220–1.681	—	—	—
T-cell response	Positive vs. negative	0.4694	0.654	0.207–2.066	—	—	—
CRP	Low (<3,000 ng/ml) vs. high	0.6543	0.790	0.282–2.217	—	—	—
IgG response	Positive vs. negative	0.8900	1.088	0.329–3.597	—	—	—

Of the 42 men 19 had death.
PPV, personalized peptide vaccination; CRPC, castration-resistance prostate cancer; CI, confidence intervals; DBC, docetaxel-based chemotherapy; ECOG, Eastern Cooperative Oncology Group; PSA, prostate-specific antigen; CRP, C reactive protein; SAA, serum amyroid A; IL6, interleukin 6.
[a]Lymphocyte, PSA and patient age are based on median values.

analysis comparing historical data. Randomized trials with an appropriate control group based on survival as the primary end point of efficacy should be required to identify this result.

In contrast to OS, the time to disease progression as defined in this study was short and did not differ significantly between the study groups. This result may be due to the delayed onset of anti-tumor responses after active immunotherapy, relative to disease progression, which occurred early in this group of patients [29]. In patients with metastatic CRPC, the disease-progression end point has not been a reliable predictor of OS. Several randomized trials that have shown effects of various treatments on OS have not shown effects on disease progression [30,31].

Cancer vaccinations do not elicit beneficial immune and/or clinical responses in all of the treated patients. Therefore, identification of surrogate biomarkers for predicting immune and/or clinical responses in vaccinated patients would be an important, but challenging issue allowing for individualized therapy. At present, however, there has been little information available regarding the predictive biomarkers identified in patients undergoing cancer vaccinations. Chronic inflammation is a key contributor to cancer development and progression [32]. Cancer survivors with chronic inflammation may have an elevated risk of recurrence as a result of the effects of inflammatory processes on cell growth or the presence of cancer cells that induce inflammation.

TABLE IV. Adverse Events

	G1	G2	G3	G4	Total
Injection site reaction	5	34	0	0	39
Lymphocytopenia	5	6	4	0	15
AST increased	12	0	2	0	14
Anemia	3	8	1	0	12
Hypoalbuminemia	7	4	0	0	11
Bone pain	2	5	2	0	9
Fatigue	2	5	0	0	7
Appetite loss	0	5	0	0	5
ALT increased	5	0	0	0	5
Blood triglycerides increased	5	0	0	0	5
Oedema peripheral	0	3	0	0	3
Renal failure	0	0	2	0	2
White blood cell count decreased	2	0	0	0	2

Elevated CRP has been associated with poor survival in metastatic prostate [33] and other cancers [34,35]. Preoperative SAA has been associated with survival in gastric cancer and renal cell carcinoma patients [36,37]. Similarly, elevated IL-6 have been associated with features of aggressive cancer and decreased survival in prostate cancer patients [38]. In this respect, we investigated whether CRP, SAA or IL-6 are predictive biomarkers for OS. Interestingly, one of the most important findings in this current study is that lower levels of IL-6 in pre-vaccine samples was significantly favorable factors for OS in the univariate and multivariate analysis. This finding suggested that this inflammatory molecule may potentially act as a surrogate biomarker for predicting a poor prognosis in patients with CRPC undergoing PPV. IL-6 is a multifunctional cytokine that regulates various aspects of the immune responses, acute phase reactions, and hematopoiesis. In particular, IL-6 has recently been reported to be one of the critical cytokines for inducing suppressive immune cell subsets [35–37]. For example, Myeloid-derived suppressive cells (MDSCs), which are known to suppress anti-tumor immunity, were shown to be rapidly generated from precursors present in murine and human bone marrow or PBMCs in the presence of IL-6 and other cytokines, such as GM-CSF [39,40]. Another combination of cytokines, IL-6 and TGF-β, were also reported to induce a recently identified subset of helper T cells, Th17, which may promote cancer progression [41–43]. Although the precise role of IL-6 in immune responses to cancer vaccines remains to be clarified, modulation or blockage of IL-6 signaling may provide benefits in patients undergoing PPV.

In conclusion, this study showed that PPV is well tolerated, and although limited responses were observed, it may have an impact on survival in CRPC patients with PD after DBC in a retrospective analysis. These encouraging preliminary results suggested that PPV warrants further study as a novel therapy for CRPC patients with PD after DBC. Importantly, this study includes an evaluation of IL-6 as an efficacy biomarker for OS in CRPC patients treated by PPV. IL-6 may potentially act as a surrogate biomarker for predicting a poor prognosis in patients with CRPC undergoing PPV, and warrants further investigation.

REFERENCES

1. National Cancer Institute. Surveillance, Epidemiology and End Results. www.seer.cancer.gov.
2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of the cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765–781.
3. Tannock I, Osaba D, Stockler M, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756–1764.
4. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and leukemia Group B 9182 study. J Clin Oncol 1999;17:2506–2513.
5. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1488–1490.
6. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351: 1513–1520.
7. Beekman KW, Fleming MT, Scher HI, Slovin SF, Ishill NM, Heller G, Kelly WK. Second-line chemotherapy for prostate cancer: Patient characteristics and survival. Clin Prostate Cancer 2005;4:86–90.
8. Mochizuki K, Sato Y, Tsuda N, Shomura H, Sakamoto M, Matsuura K, Ushijima K, Maeda Y, Katagiri K, Yamada A, Todo S, Kamura T, Harada M, Itoh K. Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen. Int J Oncol 2004;25:121–131.
9. Tsuda N, Mochizuki K, Harada M, Sukehiro A, Kawano K, Yamada A, Ushijima K, Sugiyama T, Nishida T, Yamana H, Itoh K, Kamura T. Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers. J Immunother 2004;27:60–72.
10. Noguchi M, Kakuma T, Uemura H, Nasu Y, Kumon H, Hirao Y, Moriya F, Suekane S, Matsuoka K, Komatsu N, Shichijo S, Yamada A, Itoh K. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother 2010;59:1001–1009.
11. Itoh K, Yamada A. Personalized peptide vaccines: A new therapeutic modality for cancer. Cancer Sci 2006;97:970–976.
12. Itoh K, Yamada A, Mine T, Noguchi M. Recent advances in cancer vaccines: An overview. Jpn J Clin Oncol 2009;39:73–80.
13. Harashima N, Tanaka K, Sasadomi T, Shimizu K, Miyagi Y, Yamada A, Tamura M, Yamana H, Itoh K, Shichijo S. Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of metastatic cancer patients. Eur J Immunol 2001;31:323–332.
14. Yamada A, Kawano K, Koga M, Matsumoto T, Itoh K. Multidrug resistance-associated protein 3 (MRP3) is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes. Cancer Res 2001;61:6459–6466.
15. Noguchi M, Uemura H, Naito S, Akaza H, Yamada A, Itoh K. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer. Prostate 2011;71:470–479.
16. Noguchi M, Kobayashi K, Suetsugu N, Tomiyasu K, Suekane S, Yamada A, Itoh K, Noda S. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24

positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate 2003;57:80–92.

17. Noguchi M, Itoh K, Suekane S, Yao A, Suetsugu N, Katagiri K, Yamada A, Yamana H, Noda S. Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer. Cancer Sci 2004;95:77–84.

18. Noguchi M, Itoh K, Suekane S, Morinaga A, Sukehiro A, Suetsugu N, Katagiri K, Yamada A, Noda S. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer. Prostate 2004;60:32–45.

19. Noguchi M, Itoh K, Yao A, Mine T, Yamada A, Obata Y, Furuta M, Harada M, Suekane S, Matsuoka K. Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients. Prostate 2005;63:1–12.

20. Matsueda S, Takedatsu H, Sasada T, Azuma K, Ishihara Y, Komohara Y, Noguchi M, Shichijo S, Itoh K, Harada M. New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles. J Immunother 2007;30:274–281.

21. Naito M, Komohara Y, Ishihara Y, Noguchi M, Yamashita Y, Shirakusa T, Yamada A, Itoh K, Harada M. Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles. Br J Cancer 2007;97:1648–1654.

22. Minami T, Matsueda S, Takedatsu H, Tanaka M, Noguchi M, Uemura H, Itoh K, Harada M. Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles. Cancer Immunol Immunother 2007; 56:689–698.

23. Aucouturier J, Dupuis L, Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine 2001;19:2666–2672.

24. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461–3467.

25. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumor: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–216.

26. Komatsu N, Shichijo S, Nakagawa M, Itoh K. New multiplexed flow cytometric assay to measure anti-peptide antibody: A novel tool for monitoring immune responses to peptides used for immunization. Scand J Clin Lab Invest 2004;64:1–11.

27. Noguchi M, Mine T, Yamada A, Obata Y, Yoshida K, Mizoguchi J, Harada M, Suekane S, Itoh K, Matsuoka K. Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: An analysis of prognostic factors in the treatment. Oncol Res 2007;16:341–349.

28. Mathew P, DiPaola R. Taxane refractory prostate cancer. J Urol 2007;178:S36–S41.

29. Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J.

30. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24:3089–3094.

31. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR. Overall survival analysis of a phase II randomized control trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:1099–1105.

32. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860–867.

33. McArdle PA, Mir K, Almushatat AS, Underwood MA, McMillan DC. Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol Int 2006;77:127–129.

34. Crumley AB, McMillan DC, McKerman M, Going JJ, Shearer CJ, Stuart RC. An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-esophageal cancer. Br J Cancer 2006;94:1568–1571.

35. Wong VK, Malik HZ, Hamady ZZ, Al-Mukhtar A, Gomez D, Prasad KR, Toogood GJ, Lodge JP. C-reactive protein as a predictor of prognosis following curative resection for colorectal liver metastases. Br J Cancer 2007;96:222–225.

36. Chan DC, Chen CJ, Chu HC, Chang WK, Yu JC, Chen YJ, Wen LL, Huang SC, Ku CH, Liu YC, Chen JH. Evaluation of serum amyloid A as a biomarker for gastric cancer. Ann Surg Oncol 2007;14:84–93.

37. Kimura M, Tomita Y, Imai T, Saito T, Katagiri A, Ohara-Mikami Y, Matsudo T, Takahashi K. Significance of serum amyloid A on the progression in patients with renal cell carcinoma. Cancer 2001;92:2072–2075.

38. Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001;58:1008–1015.

39. Marigo I, Bosio E, Solito S, Mesa C, Fernandez A, Dolcetti L, Ugel S, Sonda N, Bicciato S, Falisi E, Calabrese F, Basso G, Zanovello P, Cozzi E, Mandruzzato S, Bronte V. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 2010;32:790–802.

40. Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 2010; 185:2273–2284.

41. Zou W, Restifo NP. T(H)17cells in tumour immunity and immunotherapy. Nat Rev Immunol 2010;10:248–256.

42. Derhovanessian E, Adams V, Hähnel K, Groeger A, Pandha H, Ward S, Pawelec G. Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer 2009;125:1372–1379.

43. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pagès F, Galon J. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer. Cancer Res 2011;71:1263–1271.

Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010;102:1388–1397.

Original Article

Gene Expression Profiles in Peripheral Blood as a Biomarker in Cancer Patients Receiving Peptide Vaccination

Nobukazu Komatsu, PhD[1]; Satoko Matsueda, PhD[1]; Kousuke Tashiro, PhD[2]; Tetsuya Ioji, MS[1];
Shigeki Shichijo, PhD[1]; Masanori Noguchi, MD, PhD[3]; Akira Yamada, PhD[3]; Atsushi Doi, PhD[4];
Shigetaka Suekane, MD, PhD[5]; Fukuko Moriya, MD, PhD[5]; Kei Matsuoka, MD, PhD[5];
Satoru Kuhara, PhD[2]; Kyogo Itoh, MD, PhD[1]; and Tetsuro Sasada, MD, PhD[1]

BACKGROUND: Because only a subset of patients show clinical responses to peptide-based cancer vaccination, it is critical to identify biomarkers for selecting patients who would most likely benefit from this treatment. **METHODS:** The authors characterized the gene expression profiles in peripheral blood of vaccinated patients to identify biomarkers to predict patient prognosis. Peripheral blood was obtained from advanced castration-resistant prostate cancer patients, who survived for >900 days (long-term survivors, n = 20) or died within 300 days (short-term survivors, n = 20) after treatment with personalized peptide vaccination. Gene expression profiles in prevaccination and postvaccination peripheral blood mononuclear cells (PBMCs) were assessed by DNA microarray. **RESULTS:** There were no statistically significant differences in the clinical or pathological features between the 2 groups. Microarray analysis of prevaccination PBMCs identified 19 genes that were differentially expressed between the short-term and long-term survivors. Among the 15 up-regulated genes in the short-term survivors, 13 genes, which were also differentially expressed in postvaccination PBMCs, were associated with gene signatures of granulocytes. When a set of 4 differentially expressed genes were selected as the best combination to determine patient survival, prognosis was correctly predicted in 12 of 13 patients in a validation set (accuracy, 92%). **CONCLUSIONS:** These results suggested that abnormal granulocytes present in the PBMC faction may contribute to poor prognosis in advanced prostate cancer patients receiving personalized peptide vaccination. Gene expression profiling in peripheral blood might thus be informative for devising better therapeutic strategies by predicting patient prognosis after cancer vaccines. *Cancer* 2012;118:3208-21. © *2011 American Cancer Society.*

KEYWORDS: peptide vaccine, peripheral blood, biomarker, microarray, granulocyte, interleukin 6.

INTRODUCTION

Together with the progressive increase of basic knowledge in tumor immunology, the field of cancer vaccines has dramatically moved forward.[1-5] However, because only a limited number of patients show clinically beneficial responses to cancer vaccination, it would be critical to identify clinical and/or biological markers useful for selecting patients who would most likely benefit from this treatment.[5-8] Recently, polymorphisms of several genes, including *CCR5*, interferon *(IFN)*-γ, interleukin *(IL)-6*, and cytotoxic T lymphocyte antigen 4 *(CTLA-4)*, have been reported to be associated with clinical responses in nonspecific immunotherapies, such as IL-2, IFN-α, Bacille Calmette-Guérin, and anti-CTLA-4 antibody therapies.[9-12] In addition, levels of serum cytokines or growth factors, including IL-1β, IL-1α, IL-6, tumor necrosis factor (TNF)-α, CCL3, CCL4, and vascular endothelial growth factor (VEGF), have also been shown to be correlated with clinical responses in nonspecific cytokine therapies.[13,14] However, because no reliable markers are currently in widespread use for predicting clinical outcomes in specific immunotherapies, novel biomarkers remain to be identified.

Recently, high-throughput technologies have been developed as a novel approach to discovering biomarkers. In particular, DNA microarray technology is among the most widely recognized and extensively studied to identify new biomarkers for individualized therapies.[15-20] For example, gene expression profiles examined on a genome-wide scale in tumor tissues have been reported to clearly reflect clinical outcomes and/or responses to treatments in cancer patients.[15-17] In addition, expression array data of peripheral blood have also been shown to afford a comprehensive view of the patients' immune status in a variety of fields, including organ transplantation and autoimmune diseases.[18-20] However, there is little information available regarding gene expression profiles in peripheral blood of patients receiving cancer vaccines.

We have developed personalized peptide vaccination as a novel modality for cancer treatment, in which vaccine antigens are selected on the basis of pre-existing immune responses against vaccine antigens.[5,21-24] For example, our results in a recent small randomized clinical trial showed a potential clinical benefit of personalized peptide vaccination in advanced castration-resistant prostate cancer patients.[22] However, for further development of this approach, novel predictive biomarkers for selecting suitable patients with better clinical responses remain to be identified. Sipuleucel-T (Provenge; Dendreon Corporation, Seattle, Wash), an autologous active cellular immunotherapy product designed to stimulate a T-cell immune response against human prostatic acid phosphatase, was first approved for castration-resistant prostate cancer patients by the US Food and Drug Administration in 2010.[3] In this immunotherapy, CD54 up-regulation, a measure of the product's potency, has been reported to be correlated with patient overall survival.[25] However, this surrogate marker may be applicable only for dendritic cell-based immunotherapies. In the current study, we performed a gene expression profiling in peripheral blood samples of castration-resistant prostate cancer patients, who showed good or poor prognosis after personalized peptide vaccination, to identify promising biomarkers that are predictive of patient prognosis after treatment. Although it is likely that tumor tissues may have more informative gene signatures than peripheral blood mononuclear cells (PBMCs), they are usually difficult to obtain in patients with advanced castration-resistant prostate cancer. Therefore, given the ease of sampling and the ability to perform analyses at multiple time points, we used PBMCs for gene expression profiling in the current study. Our results suggested that the gene expression profiles in prevaccination PBMCs would be informative for devising better therapeutic strategies by predicting the subpopulation of castration-resistant prostate cancer patients who would most likely benefit from cancer vaccines.

MATERIALS AND METHODS
Patients
This is a retrospective analysis with peripheral blood samples from a subset of 164 patients with metastatic castration-resistant prostate cancer, who were positive for human leukocyte antigen (HLA)-A24 or HLA-A2 and enrolled in phase 1, 1-2, and 2 clinical trials for personalized peptide vaccination between February 2001 and April 2008.[22-24] These studies were approved by the ethics review committee at the participating hospitals in Japan (Kurume University Hospital, Kinki University Hospital, Okayama University Hospital, and Nara Medical University Hospital). Before enrollment in the studies, the history of all patients was studied, and physical examination, assessment of performance status, complete blood counts, serum biochemistry profiles, serum prostate-specific antigen (PSA) levels, chest radiograph, electrocardiogram, bone scan, and computerized tomography scans of the abdomen and pelvis were performed. Patients with a progression of disease (PD) after androgen ablation and second-line hormone therapy were enrolled. PD was defined by at least 1 of the following 3 criteria: 1) 2 consecutive 25% increases in PSA levels at least 2 weeks apart, 2) an increase of >25% in bidimensionally measurable soft tissue metastases, or 3) appearance of new foci on radionuclide bone scans. Other eligibility criteria included Eastern Cooperative Oncology Group performance status of 0 or 1, age of 18 years or more, normal hematologic, hepatic, and renal functions, and negative results on serologic tests for hepatitis B and hepatitis C. Patients with evidence of serious illness, an active secondary malignancy that occurred within 5 years before entry, or autoimmune diseases were excluded from the studies. After full explanation of the protocol, written informed consent was obtained from all patients before enrollment.

The right peptides for vaccination to individual patients were selected in consideration of the pre-existing host immunity before vaccination, assessed by titers of immunoglobulin (Ig)G specific to each of the 26 different vaccine candidates, as reported previously.[5,21-24] Peptides selected based on the results of peptide-specific IgG titers (3 or 4 peptides/vaccination; 3 mg/each peptide) were subcutaneously administrated with incomplete Freund

adjuvant (Montanide ISA51; Seppic, Paris, France) once per week for 6 consecutive weeks. After the first cycle of 6 vaccinations, antigen peptides, which were reselected according to the titers of peptide-specific IgG at every cycle of 6 vaccinations, were administered every 2 weeks while patients were allowed to continue the vaccinations.

Among the 164 patients enrolled, the patients who survived for >900 days (long-term survivors, n = 20) or who died within 300 days (short-term survivors, n = 20) were selected for analyses of gene expression profiles in PBMCs and soluble factors in plasma. The short-term and long-term survivors were defined in reference to a randomized, nonblinded, multinational phase 3 study of docetaxel-based regimens, TAX327, which involved 1006 men with castration-resistant prostate cancer,[26,27] because the disease conditions of castration-resistant prostate cancer patients in the TAX327 study were similar to those in the current study. Because each patient subgroup in the TAX327 study showed a median survival of 16.3 to 19.2 months,[28] we selected the patients who survived for >30 months (900 days) and who died within 10 months (300 days) as the long-term and short-term survivors, respectively, in the current study.

Blood Samples

PBMCs and plasma were used for measurement of gene expression profiles and soluble factors, respectively. Because this was a retrospective study with limited availability of patient samples, PBMCs or plasma from the patients were not equally available for each assay. Prevaccination PBMCs were analyzed by DNA microarray in all of the 40 selected patients (long-term survivors, n = 20; short-term survivors, n = 20). However, postvaccination PBMCs, which were obtained after the completion of 1 cycle of 6 vaccinations, were analyzed by DNA microarray in only a subset of the patients (long-term survivors, n = 16; short-term survivors, n = 14), because of failure in the completion of 1 cycle of vaccinations or the poor quality of purified RNA. Among these 30 postvaccination PBMCs, only 24 (long-term survivors, n = 12; short-term survivors, n = 12) were used for the quantitative real-time polymerase chain reaction (qRT-PCR) assay. Prevaccination plasma samples for soluble factor measurements were used from 36 patients (long-term survivors, n = 18; short-term survivors, n = 18).

The prevaccination PBMCs from all 40 patients were used as a training set to generate a gene classifier to predict patient prognosis. In addition, prevaccination PBMCs from 13 new independent cancer patients, who survived for >600 days (n = 6) or who died within 300

days (n = 7) after personalized peptide vaccination, were used in a validation test.

RNA Isolation From PBMCs

PBMCs were prepared from 20 mL of peripheral blood by density gradient centrifugation using Ficoll-Paque (GE Healthcare Life Sciences, Uppsala, Sweden). All samples were cryopreserved until RNA extraction. Total RNA was isolated using TRIZOL LS reagent (Invitrogen, Carlsbad, Calif) and purified using RNeasy Mini Kit (Qiagen, Valencia, Calif), according to the manufacturer's instructions. Quality and integrity of the purified total RNA were confirmed using an Agilent 2100 bioanalyzer (Agilent Technologies, Palo Alto, Calif) and Nanodrop ND-1000 (Thermo Fisher Scientific, Wilmington, Del).

DNA Microarray Analysis

RNA amplification, labeling, and hybridization on HumanWG-6 v3.0 Expression BeadChip (Illumina Bead Array; Illumina, San Diego, Calif) were performed according to the manufacturer's instructions. Microarray data were extracted using BeadStudio v3.0 software (Illumina) and were then preprocessed and normalized using a variance-stabilizing transformation and robust spline normalization, as implemented in the lumi Bioconductor package. To filter low confidence probes that might increase the false-positive rates in subsequent statistical analyses, probes that did not reach a detection level with a P value <.05 in 70% of all samples were discarded. Accordingly, of the 48,803 probes on the chips, 16,449 remained above the reliable detection level. To assess the differential gene expression between the long-term and short-term survivors, we used the fold-change ranking, together with the P values, using the Linear Models for Microarray Data (Limma) Bioconductor package.[29] To determine the fold-change in the gene expression of the samples from the long-term survivors versus those from the short-term survivors, we calculated the fold-change values using the following formula: log_2 fold-change $= log_2(S_S/S_l)$, where S_l represented the assay range for a target gene in the samples from the long-term survivors and S_S represented that from the short-term survivors. Because the gene chip used in the current study (Illumina HumanWG-6 v3.0 Expression BeadChip) contained 48,803 probes, which corresponded to 25,409 annotated genes, some genes had multiple different probes on the gene chip. Therefore, the genes with multiple probes might be repeatedly detected by different probes and identified at multiple times in the list of differentially expressed genes.

Table 1. Patient Characteristics (Postvaccination Analysis)

Characteristic	Short-Term Survivors, n = 14	Long-Term Survivors, n = 16	P
Age, y			
Median (range)	62 (50-81)	71.5 (54-78)	.109
ECOG performance status, No. [%]			
0	13 [93]	16 [100]	.467
1	1 [7]	0 [0]	
HLA typing, No. [%]			
A24	10 [71]	9 [56]	.709
A2	3 [21]	6 [38]	
A24 and A2	1 [7]	1 [6]	
PSA, ng/mL			
Median (range)	79 (2-222)	34.5 (2-330)	.308
Gleason score, No. [%]			
7	3 [21]	5 [31]	.714
8	6 [43]	8 [50]	
9	5 [36]	3 [19]	
Site of metastasis, No. [%]			
None	2 [14]	2 [13]	.888
Bone only	10 [71]	13 [81]	
Bone and lymph nodes	1 [7]	0 [0]	
Other organs	1 [7]	1 [6]	
Number of vaccinations			
Median (range)	9 (5-14)	52.5 (10-124)	<.001
Survival time, d			
Median {95% CI}	248.5 {176-277}	1482 {1120-1764}	<.001

Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HLA, human leukocyte antigen; PSA, prostate-specific antigen.

Figure 1. Volcano plots present the microarray data in prevaccination and postvaccination peripheral blood mononuclear cells (PBMCs). The plot graphs the fold-change (FC; $\log_2$[short/long]) on the x-axis versus statistical significance (minus $\log_{10}$ P value) on the y-axis in PBMCs (A) after and (B) before the peptide vaccines.

qRT-PCR

After the total RNA (200 ng) from postvaccination PBMCs (long-term survivors, n = 12; short-term survivors, n = 12) was reverse-transcribed into the first-strand cDNA with PrimeScript RT reagent kit (Takara Bio,

Shiga, Japan), qRT-PCR was performed with a SYBR Premix Ex Taq II kit (Takara Bio) by using a Thermal Cycler Dice Real Time System (Takara Bio). The data were evaluated by the ddCT method. The number of copies of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) was measured in each cDNA sample as an internal control. The expression of each gene was normalized to that of *GAPDH*. The sequences of the primers for qRT-PCR were as follows: defensin alpha 1 (*DEFA1*): forward, 5'-CGGACATCCCAGAAGTGGT TG-3', reverse, 5'-CCCTGGTAGATGCAGGTTCCA TA-3'; defensin alpha 4 (*DEFA4*): forward, 5'-CACTC CAGGCAAGAGGTGATGA-3', reverse, 5'-GAGGCA GTTCCCAACACGAAGT-3'; myeloperoxidase (*MPO*): forward, 5'-CTGCATCATCGGTACCCAGTTC-3', reverse, 5'-GATGCCTGTGTTGTCGCAGA-3'; carcinoembryonic antigen-related cell adhesion molecule 8 (*CEACAM8*): forward, 5'-TGGCACATTCCAGCAA TACACA-3', reverse, 5'-ATCATGATGCTGACAGT GGCTCTA-3'; *GAPDH*: forward, 5'-GCACCGTCA

Table 2. Differentially Expressed Genes in Postvaccination Peripheral Blood Mononuclear Cells

Gene Symbol	Gene Name	Fold-Change[a]	P[b]	Expression[c]	Before and After[d]
LTB	Lymphotoxin beta	1.03	<.001		
OLR1	Oxidized low-density lipoprotein receptor 1	1.04	.004		
CEACAM1	Carcinoembryonic antigen-related cell adhesion molecule 1	1.07	<.001	G	
ARG1	Arginase, liver	1.10	<.001	G	
MYL4	Myosin, light chain 4, alkali; atrial, embryonic	1.14	.007		
ALAS2	Delta-aminolevulinate, synthase 2	1.20	.009	E	
SLPI	Secretory leukocyte peptidase inhibitor	1.22	<.001	G	
SELENBP1	Selenium-binding protein 1	1.22	.008		
SNCA[e]	Synuclein, alpha	1.25	.008		
AZU1	Azurocidin 1	1.25	<.001	G	#
HMGXB4	HMG box domain containing 4	1.27	.001		
RNASE3	Ribonuclease, RNase A family, 3	1.28	.001	G	#
HBQ1	Hemoglobin, theta 1	1.31	.001	E	
MMP9	Matrix metallopeptidase 9	1.32	<.001	G	
GYPE	Glycophorin E	1.36	<.001	E	
SNCA[e]	Synuclein, alpha	1.39	.005		
EPB42	Erythrocyte membrane protein band 4.2	1.45	.003	E	
HP	Haptoglobin	1.50	<.001	E	
IFIT1L	Interferon-induced protein with tetratricopeptide repeats 1-like	1.51	.003		
CD24	CD24 molecule	1.55	<.001	G	
BPI	Bactericidal/permeability-increasing protein	1.64	<.001	G	
CEACAM6	Carcinoembryonic antigen-related cell adhesion molecule 6	1.72	<.001	G	#
PGLYRP1	Peptidoglycan recognition protein 1	1.80	<.001	G	#
MPO	Myeloperoxidase	1.94	<.001	G	#
OLFM4	Olfactomedin 4	2.01	<.001		
HBM	Hemoglobin, mu	2.05	.002	E	
ALAS2	Delta-aminolevulinate, synthase 2	2.11	.005	E	
CEACAM8	Carcinoembryonic antigen-related cell adhesion molecule 8	2.13	<.001	G	#
ERAF	Erythroid-associated factor	2.29	.002	E	
CA1	Carbonic anhydrase I	2.31	<.001	G	
HBD	Hemoglobin, delta	2.37	.002	E	
LCN2	Lipocalin 2	2.40	<.001	G	#
CTSG	Cathepsin G	2.40	<.001	G	#
DEFA1[e]	Defensin, alpha 1	2.40	<.001	G	#
CAMP	Cathelicidin antimicrobial peptide	2.41	<.001	G	#
ELA2	Elastase 2, neutrophil	2.44	<.001	G	#
DEFA4	Defensin, alpha 4, corticostatin	2.53	<.001	G	#
DEFA3	Defensin, alpha 3, neutrophil-specific	2.65	<.001	G	#
DEFA1[e]	Defensin, alpha 1	2.65	<.001	G	#
DEFA1[e]	Defensin, alpha 1	2.67	<.001	G	#
DEFA1[e]	Defensin, alpha 1	2.68	<.001	G	#
DEFA1[e]	Defensin, alpha 1	2.87	<.001	G	#

[a] $\log_2$ (short/long).
[b] Limma P value.
[c] Preferential expression in granulocyte (G) and erythroid cells (E).
[d] Commonly identified in both prevaccination and postvaccination peripheral blood mononuclear cells (#).
[e] Identified by multiple different probes on the gene chip.

AGGCTGAGAAC-3', reverse, 5'-TGGTGAAGACGC CAGTGGA-3'.

Measurement of Soluble Factors in Plasma

To detect the plasma levels of cytokines, chemokines, and growth factors before vaccination (long-term survivors, n = 18; short-term survivors, n = 18), a bead-based multiplex assay (xMAP; Luminex, Austin, Tex) was used. For this assay, multiple soluble factors were measured in duplicate 100 μL aliquots of plasma by using the Luminex 200 system according to the manufacturer's instructions. The analyte kit used for the measurement of the levels of multiple cytokines, chemokines, and growth factors, including IL-1Rα, IL-1β, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-15, IL-17, IFN-α, IFN-γ, TNF-α, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon-inducible protein (IP)-10,

RANTES, Eotaxin, macrophage inflammatory protein (MIP)-1α, MIP-1β, monocyte chemoattractant protein (MCP)-1, monokine induced by interferon-gamma (MIG), VEGF, endothelial growth factor (EGF), human growth factor (HGF), and basic fibroblast growth factor (FGF), was obtained from Invitrogen (Human 30-Plex).

Statistical Analysis

Mann-Whitney and Fisher exact tests were used for statistical analyses of clinical and pathological features of the patients. Overall survival was estimated by the Kaplan-Meier method and log-rank test. Mann-Whitney test was used to compare the plasma levels of cytokines, chemokines, and growth factors, and the gene expression levels in PBMCs assessed by qRT-PCR. All tests were 2-sided, and the differences with P values $<.05$ were considered statistically significant. In identification of differentially expressed genes in PBMCs, the data were assessed by the fold-change ranking, together with a nonstringent P value cutoff.[29] From the differentially expressed genes, the genes critical for accurate classification of the short-term and long-term survivors were selected by stepwise discriminant analysis method. The classification performance of the selected genes was validated in an independent test set (n = 13) by determining sensitivity, specificity, positive predictive value, negative predictive value, and accuracy. All statistical analyses were conducted using SAS version 9.1 (SAS Institute, Cary, NC).

RESULTS

Patients

We selected advanced castration-resistant prostate cancer patients who received personalized peptide vaccination and who survived for >900 days (long-term survivors, n = 20) or died within 300 days (short-term survivors, n = 20) for the DNA microarray analysis in PBMCs. For personalized peptide vaccination, different combinations of 4 peptides were selected based on the results of peptide-specific IgG titers in all patients, except for 1 patient receiving 3 peptides in the short-term survivors. Numbers of vaccinations were significantly different between the long-term (median, 50; range, 10-124) and short-term (median, 8; range, 3-14) survivors ($P < .001$). PSA doubling time calculated by the log-slope method in the long-term and short-term survivors after personalized peptide vaccination was negative in 10 (50%) of 20 and in 4 (20%) of 20 patients, respectively. In the remaining patients positive for PSA doubling time, the long-term survivors (median, 13.6; range 1.6-92.9; n = 10) had a

Figure 2. Differential gene expression was assessed by quantitative real-time polymerase chain reaction (qRT-PCR). The gene expression of (A) *DEFA1*, (B) *DEFA4*, (C) *CEACAM8*, and (D) *MPO* were measured by qRT-PCR in postvaccination peripheral blood mononuclear cells of the short-term (n = 12) and long-term (n = 12) survivors. The expression of each gene was normalized to that of *GAPDH*. The expression ratios of each gene are shown. Box plots show median and interquartile range (IQR). The whiskers (vertical bars) are the lowest value within 1.5 × IQR of the lower quartile and the highest value within 1.5 × IQR of the upper quartile. Data not included between the whiskers were plotted as outliers with dots. Two-sided P values were calculated with Mann-Whitney test.

longer PSA doubling time ($P = .006$) than the short-term survivors (median, 2.1; range, 0.7-79.0; n = 16).

Identification of Differentially Expressed Genes in Postvaccination PBMCs

We first analyzed postvaccination PBMCs by using DNA microarray analysis (HumanWG-6 v3.0 Expression Bead-Chip; 48,803 probes corresponding to 25,409 genes in total) to determine the genes that were differentially expressed between the long-term and short-term survivors. As shown in Table 1, there were no statistically significant differences in the clinical or pathological features except for the number of vaccinations ($P < .001$) and overall survival (log-rank test, $P < .001$) between the long-term (n = 16) and short-term (n = 14) survivors in whom postvaccination PBMCs were analyzed. Figure 1A shows a volcano plot that graphs the $\log_2$ fold-change on the x-axis versus the statistical significance (negative $\log_{10}$ P value) on the y-axis. When the data were assessed by fold-change ranking ($\log_2$ fold-change <-1.0 or >1.0) together with P values ($P < .01$), expressions of 42 probes, corresponding to 38 genes, were significantly altered